Agkistrodon acutus venom phospholipase A2 isoforms (AaPLA2)

Agkistrodon acutus venom phospholipase A2 (svPLA2) isoforms are a diverse group of secreted enzymes, primarily belonging to Groups IIA and IIB, found in the venom of the sharp-nosed pit viper (also known as Deinagkistrodon acutus) [1, 9]. These isoforms catalyze the hydrolysis of the sn-2 ester bond of glycerophospholipids, leading to the release of lysophospholipids and free fatty acids such as arachidonic acid, which serve as precursors for inflammatory mediators [3, 11]. Beyond their catalytic activity, these proteins exhibit potent pharmacological effects including myotoxicity, presynaptic neurotoxicity, and interference with blood coagulation and platelet aggregation [5, 12, 14]. In the clinical management of snakebite envenomation, these isoforms are critical therapeutic targets for neutralization by polyvalent or monovalent antivenoms and are the primary targets for small-molecule inhibitors like varespladib, which is currently under investigation for broad-spectrum anti-venom therapy [2, 8, 10]. Furthermore, certain isoforms are being explored as potential drug leads in oncology due to their ability to induce apoptosis in cancer cells and their synergistic effects with existing chemotherapeutic agents [4, 13].

Other names

Deinagkistrodon acutus venom phospholipase A2Five-pace snake venom PLA2Sharp-nosed pit viper venom PLA2svPLA2 isoformsAcidic phospholipase A2 (APLA2)Basic phospholipase A2 (BPLA2)Neutral phospholipase A2 (NPLA2)

Direct inhibition of the phospholipase A2 catalytic site to prevent phospholipid hydrolysis and antibody-mediated neutralization of toxin-membrane binding domains.